Details About Generic Salt ::  Medroxyp

Main Medicine Class::    

(meh-DROX-ee-pro-JESS-tuh-rone ASS-uh-TATE)

Amen

Tablets

10 mg

Curretab

Tablets

10 mg

Cycrin

Tablets

2.5 mg

Tablets

5 mg

Tablets

10 mg

Depo-Provera

Injection

150 mg/mL

Provera

Tablets

2.5 mg

Tablets

5 mg

Tablets

10 mg

Alti-MPA

class: Progestin

 Indications

PO

Treatment of secondary amenorrhea and abnormal uterine bleeding caused by hormonal imbalance.

Parenteral

Prevention of pregnancy; adjunctive and palliative treatment of inoperable, recurrent, and metastatic endometrial or renal carcinoma.

Treatment of menopausal symptoms; stimulation of respiration in obstructive sleep apnea.

 Contraindications Hypersensitivity to progestins; current or history of thrombophlebitis, thromboembolic disorders, cerebrovascular disease, or cerebral hemorrhage; impaired liver function; breast cancer; undiagnosed vaginal bleeding; missed abortion; diagnostic test for pregnancy.

 Route/Dosage

Secondary Amenorrhea

ADULTS: PO 5 to 10 mg/day for 5 to 10 days.

Abnormal Uterine Bleeding

ADULTS: PO 5 to 10 mg/day for 5 to 10 days beginning on 16th or 21st day of menstrual cycle.

Contraceptive

ADULTS: IM 150 mg q 3 mo.

Endometrial or Renal Carcinoma

ADULTS: IM 400 to 1000 mg weekly initially; maintenance: 400 mg/mo.

Interactions

Aminoglutethimide

May increase metabolism and decrease effect of medroxyprogesterone.

Lab Test Interferences Endocrine, coagulation (increased amounts of some clotting factors), thyroid and LFT results may be affected by progestins; may alter metyrapone test results; may decrease glucose tolerance.

 Adverse Reactions

CARDIOVASCULAR: Thrombophlebitis; edema. CNS: Depression; headache; nervousness; dizziness; insomnia; fatigue; somnolence. DERMATOLOGIC: Rash; acne; melasma; chloasma; alopecia; hirsutism; photosensitivity. GI: Abdominal pain or discomfort; nausea. GU: Breakthrough bleeding; spotting; change in menstrual flow; amenorrhea; decrease in libido; changes in cervical erosion and secretions. HEPATIC: Cholestatic jaundice. RESPIRATORY: Pulmonary embolism. OTHER: Breast tenderness; masculinization of female fetus; edema; weight changes, especially weight gain; anaphylactoid reactions; bone mineral density changes, increasing risk of osteoporosis; hyperglycemia.

 Precautions

Pregnancy: Category X. Lactation: Excreted in breast milk. Conception: Has prolonged contraceptive effect, which may delay time to potential conception once therapy is discontinued. Contraception: If period between injections is > 14 days, determine that patient is not pregnant before administering drug. Fluid retention: Use with careful observation when conditions that might be affected by this factor are present (eg, asthma, cardiac or renal dysfunction, epilepsy). Mental depression: Carefully observe patients with history of depression. Ophthalmic effects: Discontinue medication if there are any sudden changes in vision, sudden onset of proptosis, diplopia, migraine, papilledema, or retinal vascular lesions.

PATIENT CARE CONSIDERATIONS

 Administration/Storage

• Administer oral dose on same days of month as prescribed.
• Give medication with food if GI upset occurs.
• Parenteral dosage form is for IM administration only. Inject deeply into large muscle.
• Shake vial vigorously prior to IM administration.
• Rotate site of IM administration and observe for redness and warmth at injection site.
• When using contraceptive injection, give during first 5 days after onset of normal menstrual period or within 5 days postpartum if not breastfeeding or at 6 wk postpartum if breast feeding.
• Store at room temperature.

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies.
• Monitor serum glucose in patients with diabetes.
• Monitor results of LFTs throughout therapy.
• Assess patient’s weight daily. Notify health care provider of > 5 lb gain.
• Include breast and pelvic examination and Papanicolaou smear in pretherapy physical assessment.
• Assess BP at beginning of therapy and periodically during treatment.
• Assess fluid and respiratory status and notify health care provider of any changes.
• Notify health care provider of pain in calves accompanied by swelling, warmth, and redness; sudden severe headache; visual disturbances; numbness in extremities; signs of depression; signs of liver dysfunction (eg, dark urine, jaundice).
• Monitor mental status: affect, mood, depression, behavioral changes.
• Monitor I&O.

 Patient/Family Education

• Caution patient that this medication must not be taken during pregnancy or when pregnancy is possible. Advise patient to use reliable form of birth control while taking this drug.
• Advise patient to take tablets with food if GI upset occurs.
• Explain significance of irregular menstrual cycles, breakthrough bleeding, or change in menstrual flow, and tell patient to notify health care provider of heavy or continuous menstrual flow.
• Caution patient to avoid prolonged exposure to sunlight and other sources of ultraviolet light and to use sunscreen and wear protective clothing to avoid photosensitivity reaction.
• Encourage patients with diabetes to monitor blood glucose more frequently until effect on diabetes control is determined.
• Tell patient to notify health care provider of pain in calves with swelling, warmth, or redness; sudden severe headache; visual disturbances; numbness in extremities.
• Instruct patient to report the following symptoms to health care provider: breast abnormalities, vaginal bleeding, edema, jaundice, dark urine, clay-colored stools, dyspnea, chest pain, suspected pregnancy.
• Remind patient using agent for contraception that doses must be administered q 3 mo to ensure effectiveness.

Medicscientist Drug Facts

 

Drugs Class ::

(meh-DROX-ee-pro-JESS-tuh-rone ASS-uh-TATE)

Amen

Tablets

10 mg

Curretab

Tablets

10 mg

Cycrin

Tablets

2.5 mg

Tablets

5 mg

Tablets

10 mg

Depo-Provera

Injection

150 mg/mL

Provera

Tablets

2.5 mg

Tablets

5 mg

Tablets

10 mg

Alti-MPA

class: Progestin

Indications for Drugs ::

 Indications

PO

Treatment of secondary amenorrhea and abnormal uterine bleeding caused by hormonal imbalance.

Parenteral

Prevention of pregnancy; adjunctive and palliative treatment of inoperable, recurrent, and metastatic endometrial or renal carcinoma.

Treatment of menopausal symptoms; stimulation of respiration in obstructive sleep apnea.

Drug Dose ::

 Route/Dosage

Secondary Amenorrhea

ADULTS: PO 5 to 10 mg/day for 5 to 10 days.

Abnormal Uterine Bleeding

ADULTS: PO 5 to 10 mg/day for 5 to 10 days beginning on 16th or 21st day of menstrual cycle.

Contraceptive

ADULTS: IM 150 mg q 3 mo.

Endometrial or Renal Carcinoma

ADULTS: IM 400 to 1000 mg weekly initially; maintenance: 400 mg/mo.

Contraindication ::

 Contraindications Hypersensitivity to progestins; current or history of thrombophlebitis, thromboembolic disorders, cerebrovascular disease, or cerebral hemorrhage; impaired liver function; breast cancer; undiagnosed vaginal bleeding; missed abortion; diagnostic test for pregnancy.

Drug Precautions ::

 Precautions

Pregnancy: Category X. Lactation: Excreted in breast milk. Conception: Has prolonged contraceptive effect, which may delay time to potential conception once therapy is discontinued. Contraception: If period between injections is > 14 days, determine that patient is not pregnant before administering drug. Fluid retention: Use with careful observation when conditions that might be affected by this factor are present (eg, asthma, cardiac or renal dysfunction, epilepsy). Mental depression: Carefully observe patients with history of depression. Ophthalmic effects: Discontinue medication if there are any sudden changes in vision, sudden onset of proptosis, diplopia, migraine, papilledema, or retinal vascular lesions.

PATIENT CARE CONSIDERATIONS

Drug Side Effects ::

 Adverse Reactions

CARDIOVASCULAR: Thrombophlebitis; edema. CNS: Depression; headache; nervousness; dizziness; insomnia; fatigue; somnolence. DERMATOLOGIC: Rash; acne; melasma; chloasma; alopecia; hirsutism; photosensitivity. GI: Abdominal pain or discomfort; nausea. GU: Breakthrough bleeding; spotting; change in menstrual flow; amenorrhea; decrease in libido; changes in cervical erosion and secretions. HEPATIC: Cholestatic jaundice. RESPIRATORY: Pulmonary embolism. OTHER: Breast tenderness; masculinization of female fetus; edema; weight changes, especially weight gain; anaphylactoid reactions; bone mineral density changes, increasing risk of osteoporosis; hyperglycemia.

Drug Mode of Action ::  

(meh-DROX-ee-pro-JESS-tuh-rone ASS-uh-TATE)

Amen

Tablets

10 mg

Curretab

Tablets

10 mg

Cycrin

Tablets

2.5 mg

Tablets

5 mg

Tablets

10 mg

Depo-Provera

Injection

150 mg/mL

Provera

Tablets

2.5 mg

Tablets

5 mg

Tablets

10 mg

Alti-MPA

class: Progestin

Drug Interactions ::

Interactions

Aminoglutethimide

May increase metabolism and decrease effect of medroxyprogesterone.

Drug Assesment ::

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies.
• Monitor serum glucose in patients with diabetes.
• Monitor results of LFTs throughout therapy.
• Assess patient’s weight daily. Notify health care provider of > 5 lb gain.
• Include breast and pelvic examination and Papanicolaou smear in pretherapy physical assessment.
• Assess BP at beginning of therapy and periodically during treatment.
• Assess fluid and respiratory status and notify health care provider of any changes.
• Notify health care provider of pain in calves accompanied by swelling, warmth, and redness; sudden severe headache; visual disturbances; numbness in extremities; signs of depression; signs of liver dysfunction (eg, dark urine, jaundice).
• Monitor mental status: affect, mood, depression, behavioral changes.
• Monitor I&O.

Drug Storage/Management ::

 Administration/Storage

• Administer oral dose on same days of month as prescribed.
• Give medication with food if GI upset occurs.
• Parenteral dosage form is for IM administration only. Inject deeply into large muscle.
• Shake vial vigorously prior to IM administration.
• Rotate site of IM administration and observe for redness and warmth at injection site.
• When using contraceptive injection, give during first 5 days after onset of normal menstrual period or within 5 days postpartum if not breastfeeding or at 6 wk postpartum if breast feeding.
• Store at room temperature.

Drug Notes ::

 Patient/Family Education

• Caution patient that this medication must not be taken during pregnancy or when pregnancy is possible. Advise patient to use reliable form of birth control while taking this drug.
• Advise patient to take tablets with food if GI upset occurs.
• Explain significance of irregular menstrual cycles, breakthrough bleeding, or change in menstrual flow, and tell patient to notify health care provider of heavy or continuous menstrual flow.
• Caution patient to avoid prolonged exposure to sunlight and other sources of ultraviolet light and to use sunscreen and wear protective clothing to avoid photosensitivity reaction.
• Encourage patients with diabetes to monitor blood glucose more frequently until effect on diabetes control is determined.
• Tell patient to notify health care provider of pain in calves with swelling, warmth, or redness; sudden severe headache; visual disturbances; numbness in extremities.
• Instruct patient to report the following symptoms to health care provider: breast abnormalities, vaginal bleeding, edema, jaundice, dark urine, clay-colored stools, dyspnea, chest pain, suspected pregnancy.
• Remind patient using agent for contraception that doses must be administered q 3 mo to ensure effectiveness.

Medicscientist Drug Facts

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.